Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of November 1, 2024, at 4:30 P.M. This form is a registration statement that allows the company to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that the SEC has reviewed and accepted the company's registration, which is a crucial step for Conduit Pharmaceuticals in its efforts to raise capital and expand its financial flexibility.

Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of November 1, 2024, at 4:30 P.M. This form is a registration statement that allows the company to issue various securities, including stocks and bonds, to the public. The effectiveness of this form indicates that the SEC has reviewed and accepted the company's registration, which is a crucial step for Conduit Pharmaceuticals in its efforts to raise capital and expand its financial flexibility.